Bioverativ Inc. Common Stock
BIVV
BIVV was delisted on the 8th of March, 2018.
452 hedge funds and large institutions have $5.94B invested in Bioverativ Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 78 funds opening new positions, 127 increasing their positions, 162 reducing their positions, and 86 closing their positions.
12% more capital invested
Capital invested by funds: $5.28B → $5.94B (+$659M)
11% more call options, than puts
Call options by funds: $22.8M | Put options by funds: $20.6M
9% less first-time investments, than exits
New positions opened: 78 | Existing positions closed: 86
3% less funds holding
Funds holding: 467 → 452 (-15)
22% less repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 162
56% less funds holding in top 10
Funds holding in top 10: 9 → 4 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$179M |
| 2 |
HM
HealthCor Management
New York
|
+$84M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$67.6M |
| 4 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$67.6M |
| 5 |
Goldman Sachs
New York
|
+$66.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIG
Senator Investment Group
New York
|
-$170M |
| 2 |
Millennium Management
New York
|
-$98.5M |
| 3 |
VH
ValueAct Holdings
San Francisco,
California
|
-$74.8M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$54.4M |
| 5 |
NM
Newtyn Management
New York
|
-$43.6M |
BIVV Hedge Fund Activity: Q2 2017 in Review
452 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Bioverativ Inc. Common Stock (BIVV) for Q2 2017, worth a combined $5.94B — up 12% from $5.28B a quarter earlier.
Sellers outnumbered buyers: 86 funds closed out of BIVV and 78 opened new positions — a net loss of 8 holders — while 162 trimmed existing stakes and 127 added.
The largest buyer was Fidelity Investments, adding an estimated $179M. The largest seller was Senator Investment Group, exiting entirely with an estimated $170M sold.
- 452 institutional investors held Bioverativ Inc. Common Stock (BIVV) as of Q2 2017, down from 467 in Q1 2017.
- Funds reported $5.94B of Bioverativ Inc. Common Stock stock for Q2 2017, up 12% quarter-over-quarter.
- 78 funds opened new Bioverativ Inc. Common Stock positions in Q2 2017 and 86 closed out, a net change of -8 holders.
- The largest Bioverativ Inc. Common Stock buyer in Q2 2017 was Fidelity Investments, an estimated $179M added.
- The largest Bioverativ Inc. Common Stock seller in Q2 2017 was Senator Investment Group, an estimated $170M sold.
Based on aggregated 13F filings for Q2 2017.